This morning we're excited to announce the appointment of Dr. Wendy Yeh as NGM Bio's Chief Medical Officer! As an experienced drug developer and a skilled clinician, Wendy has a profound passion to address unmet patient needs through the advancement of innovative therapeutics.?She will oversee the clinical, regulatory and biometrics functions at NGM and lead the clinical development of our key programs, NGM120 for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis. Welcome, Wendy! Read the press release: https://lnkd.in/eZa3tHbH #HyperemesisGravidarum #CancerCachexia #Cachexia #PrimarySclerosingCholangitis ?
NGM Biopharmaceuticals
生物技术研究
South San Francisco，CA 9,844 位关注者
Explorers on the frontier of life-changing science.
关于我们
NGM Bio is a biopharmaceutical company focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. In addition to a healthy balance sheet and cash runway, the company currently has four programs in active clinical development. Visit us at www.ngmbio.com for more information.
- 网站
-
https://www.ngmbio.com
NGM Biopharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，CA
- 类型
- 上市公司
- 创立
- 2008
地点
-
主要
获取路线
333 Oyster Point Blvd.
US，CA，South San Francisco，94080
NGM Biopharmaceuticals员工
-
Jean-Frederic Viret
-
Linda Tsang
Sr. Executive Administrator | C-Suite & BOD | Int'l Travel Mgmt | Arrange & Engage | Events Director | Financial Fluency | Tech Enthusiast
-
Connie Merron
Associate Director, Research Informatics
-
Carrie Shiau
Director, Business Development at NGM Biopharmaceuticals
动态
-
This morning we're excited to announce the appointment of Dr. Wendy Yeh as NGM Bio's Chief Medical Officer! As an experienced drug developer and a skilled clinician, Wendy has a profound passion to address unmet patient needs through the advancement of innovative therapeutics.?She will oversee the clinical, regulatory and biometrics functions at NGM and lead the clinical development of our key programs, NGM120 for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis. Welcome, Wendy! Read the press release: https://lnkd.in/eZa3tHbH #HyperemesisGravidarum #CancerCachexia #Cachexia #PrimarySclerosingCholangitis ?
-
We're excited to announce the signing of a worldwide license agreement with KdT Ventures for NGM313, a Phase 2-ready FGFR1c/β-Klotho receptor complex agonistic antibody, which was discovered by NGM Bio. KdT has formed a new company to develop NGM313 in a #raredisease, representing the first non-metabolic indication for which NGM313 will be evaluated. The new company plans to initiate a Phase 2 proof-of-concept study in 2025. We look forward to collaborating with KdT and are excited for NGM313’s next chapter under the stewardship of KdT’s new venture. Read the press release: https://lnkd.in/gt4m4zv4
-
Our Sr. Vice President of CMC and Process Development, Kara Calhoun, will moderate a panel on Monday, Sept. 30 at 4:00 - 4:45 pm ET at the? #FierceBiotechSummit in Boston. This panel of industry leaders will explore how biotech companies can strategically leverage CDMO partnerships to drive innovation, efficiency and success in drug development and manufacturing. ? Visit the event website to view the full agenda:? https://lnkd.in/gtM6CwrF ? See you in Boston! ?
-
-
We're thrilled to announce a?$122M Series A financing, led by The Column Group with participation from a select group of investors. Read press release: https://bit.ly/3LuwvU4 ? These funds will enable us to initiate a planned registrational trial of aldafermin for the treatment of primary sclerosing cholangitis and complete a planned Phase 2 proof-of-concept trial for the treatment of hyperemesis gravidarum (HG) - both expected to begin in Q4 2024.? ? PSC is a rare liver disease that irreparably damages the bile ducts, leading to bile acid dysregulation and, ultimately, severe liver damage. HG?is a rare, debilitating condition of pregnancy, characterized by intractable nausea and uncontrollable vomiting and frequent, serious complications.? ? There are no currently approved therapies for PSC or HG. #primarysclerosingcholangitis #hyperemesisgravidarum #hyperemesis
-
-
I'm hiring! Check out this opportunity if working in the People and Culture team is your passion, not just a job! https://lnkd.in/g7D5Mq9v